Latest news with #QuansysBiosciences
The Australian
4 days ago
- Health
- The Australian
Breakthrough for Rhythm's next-gen bowel test
ColoSTAT diagnostic performance consistent across colorectal cancer I to IV stages Performance meets clinical requirements for symptomatic patient testing use case Commercialisation steps underway as ColoSTAT kit transitioned to final production validation state Special Report: Rhythm Biosciences has announced that its second-generation ColoSTAT blood test detects colorectal cancer consistently across all stages of the disease, marking an important milestone as the company prepares for commercialisation later this year. Following completion of ColoSTAT Beta kit verification and validation announced in May, the Rhythm Biosciences (ASX:RHY) development team has received a batch of ColoSTAT kits produced by Quansys Biosciences using the final manufacturing process. As part of the validation process, blood samples from 300 patients, ranging from those without bowel cancer to those with stage I to IV of the disease, were tested to assess how well ColoSTAT works across all stages. While further studies will be completed, the results show the test is equally effective at detecting colorectal cancer at every stage, which is an important finding given its intended use for symptomatic patients who could have either early- or late-stage cancer tests often struggle to detect early-stage disease, so the fact that ColoSTAT performs well at this stage is seen as particularly important. The predictive cancer diagnostics technology company expects to finalise validation of the kits, algorithm, and instrumentation in the near term, ahead of a submission to the National Association of Testing Authorities (NATA) in Australia to include ColoSTAT in its ISO15189 laboratory test portfolio. NATA is Australia's primary accreditation body for laboratories and testing facilities. Commercial launch of ColoSTAT is planned for later in CY25, subject to NATA regulatory approval. Watch: CEO David Atkin's talks about early cancer detection. 'Establishing a clinically useful product' ColoSTAT is a simple, minimally invasive blood test designed for people unwilling or unable to undergo traditional screening methods for colorectal (bowel) cancer, the world's second leading cause of cancer deaths but highly treatable when detected early. The test identifies specific protein biomarkers in the blood that indicate the likelihood of colorectal cancer. The second-generation ColoSTAT blood test involved a redesign of the assay from a single-plex into a multiplex format with several objectives including: Simplify completion of the test for a routine laboratory Reduce turnaround times (TAT) Improve the quality and performance of the assay Reduce overall cost of goods for the assay Clinical advisor Dr Andy Feber said demonstrating performance across the full spectrum of neoplastic conditions was essential for a clinically useful product. 'Establishing ColoSTAT performance across the entire range of neoplastic conditions is an important requirement for a clinically useful product,' he said. 'I'm pleased to see this important milestone has been achieved.' This article was developed in collaboration with Rhythm Biosciences, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Business Wire
29-07-2025
- Business
- Business Wire
Quansys Biosciences Launches Q-View™ Imager Plus: Delivering Reproducible, high-impact ELISA Data with Ease
LOGAN, Utah--(BUSINESS WIRE)--Quansys Biosciences, a leader in multiplex immunoassay technology, today announced the launch of the Q-View™ Imager Plus, a next-generation imaging device designed to deliver reproducible, high-resolution ELISA results with streamlined workflows. Paired with the newly upgraded Q-View™ Software, the platform combines advanced imaging hardware with powerful and user-friendly analysis tools built to help academic, biopharma, and clinical laboratories generate reliable, publication quality, and regulation-ready data with speed and confidence. The new Q-View Imager Plus, along with the updated Q-View Software, provide consistent, high-quality data, for use in academic, biopharma, and clinical laboratories. Share At the core of the Q-View™ Imager Plus is a 35-megapixel multi-camera system with temperature-controlled sensors, offering high resolution images and consistent data quality across every plate. This design ensures reliable performance for both research and regulated laboratory environments, making it one of the most advanced imaging solutions in its class. 'We designed the Q-View™ Imager Plus and its upgraded Q-View™ Software to provide labs with consistent, high-quality data,' said Adam Brown, CEO at Quansys Biosciences. 'By combining advanced imaging with power and intuitive analysis tools, we have been able to deliver on our commitment to empower labs with tools that simplify complex workflows and deliver high-impact results, faster.' While most plate readers merely scan data points, the Q-View™ Imager Plus captures crystal-clear photographic images of 96-well plates and processes them in real time, allowing scientists to extract more meaningful results with less variability. The improved system extracts richer data with confidence, with active cooling ensuring consistent data from one image to the next, which is an essential requirement for clinical and regulatory settings. Key features include: Pre-focused optics for plug-and-play performance Integrated barcode scanning for automatic plate identification and reduced user error Internal qualification lighting for precise calibration without the need for external powered devices Durable and compact design, ideal for crowded lab environments Energy-saving mode to minimize wear, energy use, and noise when idle Compatible with automation and liquid handlers for high-throughput labs Field-upgradable firmware ensures longevity and adaptability 'Our goal with the Q-View Imager Plus was to give scientists a tool that combines high-quality imaging with practical usability,' said Dr. Kyle Berg PhD, who leads the R&D team at Quansys Biosciences. 'Every feature, from the pre-focuses optics to the integrated software, was engineered to reduce variability and make multiplex ELISA workflows faster and more reliable.' Availability The Q-View™ Imager Plus is now available for purchase worldwide. To request pricing or more information, visit or contact sales@ About Quansys Biosciences Quansys Biosciences is a leading biotechnology company specializing in multiplex ELISA testing solutions and quantitative protein analysis for both research and clinical applications. Its Q-Plex™ product line, Q-View™ Software, and Q-View™ Imagers are trusted by scientists and clinicians around the world to study a wide range of diseases, including infectious diseases, cancer, and autoimmune disorders. By delivering tools that improve efficiency, accuracy, and insight, Quansys empowers laboratories to generate high-quality biomarker data with confidence.
